WeChat Mini Program
Old Version Features

274 Development of CTX112 a Next Generation Allogeneic Multiplexed CRISPR-edited CART Cell Therapy with Disruptions of the TGFBR2 and Regnase-1 Genes for Improved Manufacturing and Potency

Sarah Cohen,Jacob Waldman PK Morrow, Mark Benton

Journal for ImmunoTherapy of Cancer(2023)

4Sparta Science

Cited 0|Views20
Abstract
Background CTX110, a CD19-directed first-generation CRISPR-edited CAR T cell therapeutic candidate for B-cell lymphoma, has induced clinical responses and durable remissions (2+ years) in some patients (CARBON trial, NCT04035434). CTX112 contains the same edits as CTX110 to disrupt the B2M locus for immune evasion and the TRAC locus to prevent GvHD and allow for CAR transgene integration. Additionally, CTX112 contains disruptions in the TGFBR2 gene to avoid immune suppression of CAR T activity by cells of the tumor environment and the Regnase-1 gene to increase functional persistence. This increase in functional persistence was also assessed for increased manufacturing yields. Methods CTX112 was produced utilizing CRISPR/Cas9 gene editing to disrupt genomic loci, and AAV6 vector to introduce donor template for CAR integration. Manufacturing was performed similarly to CTX110 but CTX112 was also used as a seed bank to generate upwards of 20X more product. Functional assessment of standard and extended cultures of CTX112 was performed in vitro as well as in vivo for anti-B-cell lymphoma/leukemia activity against several cell lines, including Nalm6, Raji and Jeko-1. Safety and immunogenicity of the engineered cells were assessed in vitro by cytokine independent growth and in vivo in toxicology studies in NSG mice. Results CTX112 is at least 10x more potent than CTX110 in xenograft models. CTX112 cells secrete high levels of a broad array of cytokines, resist TGFβ inhibition, have a higher proliferative potential and are more sensitive to cytokines. CTX112 does not display cytokine independent growth but displays greater expansion during manufacturing. Conclusions CTX112 is a more potent next generation anti CD19 CAR T cell that also shows improved manufacturability. The lack of class I MHC on CTX112 could enable rejection by patient NK cells but such cells are rare and show little activity at tumor sites. Thus, we hypothesize that CTX112 will show increased functional persistence at the site of tumor and will continue to kill cancer cells for longer as compared to other allogeneic CAR T cell products through its persistent effector function and TME suppression resistance. CTX112 is being evaluated in a clinical trial for B cell malignancies (NCT05643742).
More
Translated text
求助PDF
上传PDF
Bibtex
AI Read Science
AI Summary
AI Summary is the key point extracted automatically understanding the full text of the paper, including the background, methods, results, conclusions, icons and other key content, so that you can get the outline of the paper at a glance.
Example
Background
Key content
Introduction
Methods
Results
Related work
Fund
Key content
  • Pretraining has recently greatly promoted the development of natural language processing (NLP)
  • We show that M6 outperforms the baselines in multimodal downstream tasks, and the large M6 with 10 parameters can reach a better performance
  • We propose a method called M6 that is able to process information of multiple modalities and perform both single-modal and cross-modal understanding and generation
  • The model is scaled to large model with 10 billion parameters with sophisticated deployment, and the 10 -parameter M6-large is the largest pretrained model in Chinese
  • Experimental results show that our proposed M6 outperforms the baseline in a number of downstream tasks concerning both single modality and multiple modalities We will continue the pretraining of extremely large models by increasing data to explore the limit of its performance
Upload PDF to Generate Summary
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn
Chat Paper
Summary is being generated by the instructions you defined